ESMO Advanced Course on Precision Oncology in Breast Cancer

PROGRAMME
LEARNING OBJECTIVES

- To understand the function and biology of the most relevant driver molecular alterations in early and metastatic breast cancer
- To gain insights in the spectrum of breast cancer molecular aberrations, platforms, and strategies for molecular testing
- To provide information and in-depth discussion on the state-of-the-art and emerging therapeutic strategies integrating major germline or somatic mutations, driving oncogene addiction in early and metastatic breast cancer
- To present novel data on biomarkers of benefit, mechanisms of resistance and combinatorial therapeutic strategies for metastatic breast cancer

ACCREDITATION

The programme of this event has been accredited with 10 ESMO-MORA category 1 points.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from

Lilly

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org
Friday, 9 June 2023

09:00-09:10 Welcome and introduction
10’ Welcome and learning objectives introduction
Ana Bosch, SE and Giuseppe Curigliano, IT

09:10-10:35 Session 1 – Molecular targets in ER+ disease – ESR1 mutations
Chair: Giuseppe Curigliano, IT

15’ ER – Biology of the target / biomarker
Nicholas Turner, UK

15’ Update on the clinical efficacy of targeted agents: Indications, efficacy and toxicity
Giuseppe Curigliano, IT

15’ ESR1 mutations – Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation)
Nicholas Turner, UK

10’ Q&A

15’ A clinicopathological case presented and discussed by a Molecular Tumour Board
Giuseppe Curigliano, IT

15’ Q&A and Chair conclusion

10:35-11:05 Coffee break

11:05-12:45 Session 2 – Molecular targets in ER+ disease – PIK3CA and AKT pathway
Chair: Ana Bosch, SE

30’ The PI3K Pathway – Insights into the biology and clinical research
Ana Bosch, SE

15’ Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation)
Mafalda Oliveira, ES

10’ Q&A

15’ A clinicopathological case presented and discussed by a Molecular Tumour Board
Mafalda Oliveira, ES

10’ Q&A

15’ Value / health economics of testing and targeting (incl. MCBS, ESCAT actionability, RWD) for ESR1, PIK3CA and AKT
Dario Trapani, IT

5’ Chair conclusion

12:45-13:45 Lunch

13:45-15:25 Session 3 – Molecular targets in TNBC disease – TILs, PDL1 and Ki 67
Chair: Giancarlo Pruneri, IT

20’ Biology of the target / biomarker
Giancarlo Pruneri, IT

20’ Update on the clinical efficacy of targeted agents: Indications, efficacy and toxicity
Barbara Pistilli, FR

20’ Testing for the target / biomarker (assays, technicalities and practicalities, challenges for interpretation)
Giancarlo Pruneri, IT

10’ Q&A

15’ A clinicopathological case presented and discussed by a Molecular Tumour Board
Barbara Pistilli, FR

15’ Q&A and Chair conclusion

15:25-15:55 Coffee break
15:55-17:40  
**Session 4 – Molecular targets in TNBC disease – BRCA/PALB2 germinal and somatic mutations**  
Chair: Giuseppe Curigliano, IT

30’ Biology and testing of biomarkers for targeted therapy in TNBC  
Judith Balmaña, ES

15’ Update on the clinical efficacy of targeted agents: Indications, efficacy and toxicity  
Cristina Saura, ES

10’ Q&A

15’ A clinicopathological case presented and discussed by a Molecular Tumour Board  
Cristina Saura, ES

20’ Value / health economics of testing and targeting (incl. MCBS, ESCAT actionability, RWD) for PDL1, BRCA, Ki67 and TILs  
Dario Trapani, IT

5’ Chair conclusion

19:30  
**Networking Dinner**

---

**Saturday, 10 June 2023**

09:00-10:50  
**Session 5 – HER2 as a target in breast cancer**  
Chair: Giuseppe Curigliano, IT

20’ Update on the clinical treatment algorithm in HER2 positive disease (early and metastatic)  
Javier Cortés, ES

20’ HER2 pathway: Testing HER2 expression and HER2 mutations  
Aleix Prat, ES

20’ HER2 low disease – Clinical trials and challenges in testing  
Giuseppe Curigliano, IT

20’ Q&A

15’ Value / health economics of testing and targeting (incl. MCBS, ESCAT actionability, RWD)  
Dario Trapani, IT

15’ Q&A and Chair conclusion

10:50-11:20  
**Coffee break**

11:20-12:15  
**Session 6 – Genomics in breast cancer management**  
Chair: Ana Bosch, SE

15’ Role of genomic assays in early breast cancer  
Aleix Prat, ES

15’ Integrating NGS in treatment selection for metastatic breast cancer (solid biopsy vs ctDNA)  
Mafalda Oliveira, ES

15’ Role of genomic assays in metastatic setting: A focus on immunotherapy  
Giuseppe Curigliano, IT

10’ Q&A

12:15-12:30  
**Synthesis and wrap-up**

12:30-13:30  
**Lunch**